Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR).
暂无分享,去创建一个
N. Wong | A. Goyal | Darren K Mcguire | S. Arnold | N. Hammar | S. Inzucchi | S. Mehta | F. Tang | C. Lam | P. Fenici | M. Kosiborod | L. Sperling | Abhinav Goyal
[1] S. Arnold,et al. Cardiovascular Outcomes and Mortality in Type 2 Diabetes with Associated Cardio-Renal-Metabolic Comorbidities , 2018, Diabetes.
[2] Charles E. Leonard,et al. Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: A retrospective cohort study , 2018, Pharmacoepidemiology and drug safety.
[3] M. Boemi,et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. , 2017, The lancet. Diabetes & endocrinology.
[4] K. Mahaffey,et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.
[5] K. Khunti,et al. Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study , 2017 .
[6] K. Khunti,et al. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs , 2017, Circulation.
[7] 8. Pharmacologic Approaches to Glycemic Treatment , 2016, Diabetes Care.
[8] David W. Johnson,et al. Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis. , 2016, JAMA.
[9] N. Wong,et al. Evaluating the Quality of Comprehensive Cardiometabolic Care for Patients With Type 2 Diabetes in the U.S.: The Diabetes Collaborative Registry , 2016, Diabetes Care.
[10] S. Hutfless,et al. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes , 2016, Annals of Internal Medicine.
[11] J. Gross,et al. The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials , 2016, PLoS medicine.
[12] S. Hutfless,et al. Diabetes Medications for Adults With Type 2 Diabetes: An Update , 2016 .
[13] D. Tanné,et al. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. , 2016, The New England journal of medicine.
[14] A. Shillington,et al. Effect of a patient decision aid (PDA) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflict , 2015, BMC Health Services Research.
[15] B. Zinman,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.
[16] J. Spertus,et al. Glucose-Lowering Medications and Angina Burden in Patients with Stable Coronary Disease: results from the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) Trial. , 2015, American heart journal.
[17] B. Vandermeer,et al. Mortality risk among sulfonylureas: a systematic review and network meta-analysis. , 2015, The lancet. Diabetes & endocrinology.
[18] F. Hu,et al. Sulfonylurea Use and Incident Cardiovascular Disease Among Patients With Type 2 Diabetes: Prospective Cohort Study Among Women , 2014, Diabetes Care.
[19] F. Haaijer-Ruskamp,et al. Effects of a patient oriented decision aid for prioritising treatment goals in diabetes: pragmatic randomised controlled trial , 2014, BMJ : British Medical Journal.
[20] D. Matthews,et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.
[21] D. Matthews,et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.
[22] A. Vaag,et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. , 2011, European heart journal.
[23] B. Wells,et al. The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy , 2010, Diabetes Care.
[24] Gordon H Guyatt,et al. The diabetes mellitus medication choice decision aid: a randomized trial. , 2009, Archives of internal medicine.
[25] B. Zinman,et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy , 2008, Diabetologia.
[26] Y. Jang,et al. Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .
[27] Sander Greenland,et al. Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies. , 2004, American journal of epidemiology.
[28] G. Zou,et al. A modified poisson regression approach to prospective studies with binary data. , 2004, American journal of epidemiology.